Table 1.
Baseline characteristics of patients treated with entecavir or TDF
| Variables | Entecavir n = 993 | TDF n = 567 | p value |
|---|---|---|---|
| Age (year) | 55.4 ± 11.7 | 54.5 ± 12.9 | 0.190 |
| Sex, male | 721 (72.6%) | 428 (75.5%) | 0.215 |
| HBeAg-positive status | 209 (21.0%) | 130 (22.9%) | 0.377 |
| Decompensation status | 182 (18.3%) | 58 (10.2%) | < 0.001 |
| NA-naïve | 875 (88.1%) | 478 (84.3%) | 0.033 |
| Diabetes mellitus, yes | 232 (23.4%) | 89 (15.7%) | < 0.001 |
| Hypertension, yes | 280 (28.2%) | 131 (23.1%) | 0.028 |
| HBV DNA, log10 IU/mL | 5.42 ± 1.49 | 5.37 ± 1.44 | 0.534 |
| AST, U/L | 117.4 ± 214.3 | 113.1 ± 262.9 | 0.727 |
| ALT, U/L | 139.1 ± 268.5 | 151.7 ± 386.1 | 0.448 |
| Total bilirubin, mg/dL | 2.04 ± 3.84 | 1.57 ± 2.88 | 0.011 |
| Albumin, g/dL | 3.91 ± 0.65 | 4.07 ± 0.57 | < 0.001 |
| INR | 1.20 ± 0.28 | 1.17 ± 0.24 | 0.018 |
| eGFR, mL/min/1.73 m2 | 85.4 ± 29.9 | 98.0 ± 52.2 | < 0.001 |
| Platelet, ×103/μL | 131.1 ± 55.7 | 150.4 ± 57.1 | < 0.001 |
| AFP, ng/mL | 32.0 ± 118.4 | 31.6 ± 113.8 | 0.952 |
| Child-Pugh score | 5.89 ± 1.60 | 5.49 ± 1.19 | < 0.001 |
| FIB-4 | 5.13 ± 5.43 | 3.69 ± 3.84 | < 0.001 |
| APRI | 3.17 ± 6.42 | 2.59 ± 6.55 | 0.090 |
AFP, alpha-fetoprotein; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; FIB-4, fibrosis index based on four factors; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; INR, international normalized ratio; NA, nucleos(t)ide analogue; TDF, Tenofovir disoproxil fumarate.